ResMed (RMD) vs West Pharmaceutical Services (WST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
West Pharmaceutical Services (WST) has outperformed ResMed (RMD) over the past year, gaining 37.8% versus a loss of 20.2%. Over five years, WST leads with a -9.5% price change compared with -11.6% for RMD. ResMed is the larger company by market cap ($31.89 billion vs $25.57 billion), about 1.2 times the size.
On valuation, ResMed trades at a lower forward P/E (17.1x vs 36.3x for West Pharmaceutical Services). ResMed offers the higher dividend yield (1.06% vs 0.24%). ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 16.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RMD | WST |
|---|---|---|
| Share price | $226.73 | $363.27 |
| Market cap | $31.89B | $25.57B |
| 1-day change | +0.33% | -0.88% |
| YTD return | -6.18% | +33.20% |
| 1-year return | -20.23% | +37.79% |
| 5-year return | -11.55% | -9.47% |
| P/E ratio (TTM) | 21.74 | 46.51 |
| Forward P/E | 17.14 | 36.35 |
| EPS (TTM) | $10.43 | $7.81 |
| Dividend yield | 1.06% | 0.24% |
| Annual dividend | $2.40 | $0.87 |
| Revenue (latest FY) | $5.65B | $3.07B |
| Revenue growth (YoY) | +9.85% | +6.25% |
| Net income (latest FY) | $1.52B | $493.70M |
| Gross margin | 61.06% | 35.91% |
| Operating margin | 33.37% | 19.03% |
| Net margin | 26.94% | 16.06% |
| 52-week high | $284.05 | $386.00 |
| 52-week low | $180.27 | $223.83 |
| Distance from 52-week high | -20.18% | -5.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +10.36% | +13.14% |
| Average volume | 1.34M | 626.98K |
| Shares outstanding | 140.64M | 70.38M |
| Employees | 11,370 | 10,800 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WST has outperformed RMD by 58.0 percentage points over the past year.
- West Pharmaceutical Services trades at a higher earnings multiple (46.5x vs 21.7x trailing P/E).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 16.1 cents for West Pharmaceutical Services.
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
About West Pharmaceutical Services
WST stock →West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 10,800 employees
RMD vs WST FAQ
Which is bigger, ResMed or West Pharmaceutical Services?
ResMed (RMD) is larger, with a market capitalization of $31.89B compared with $25.57B for West Pharmaceutical Services (WST).
Which stock has performed better over the past year, RMD or WST?
WST returned +37.79% over the past 12 months, compared with -20.23% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RMD or WST?
RMD has the lower trailing P/E at 21.7, versus 46.5 for WST. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, ResMed or West Pharmaceutical Services?
ResMed has the higher yield at 1.06%, compared with 0.24% for West Pharmaceutical Services.
Are ResMed and West Pharmaceutical Services in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.